Statins reduce risk of cardiovascular disease (CVD) by decreasing plasma LDL concentrations, as well as reducing inflammation and improving endothelial function. Despite their documented efficacy, there is considerable interindividual variation in effects of statins on CVD biomarkers. In the studies summarized here we used complementary metabolomics platforms to define global effects of a statin (simvastatin) on metabolism and to identify markers indicative of mechanisms that contribute to variation in plasma LDL response to statin treatment.Clinical Pharmacology & Therapeutics (2013); accepted article preview online 14 August 2013 doi:10.1038/clpt.2013.164.
[ hide abstract ]
Reminder: you don't need to add entities already covered in variant annotations -- they'll be added automatically.